Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months

We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or no symptoms. The first infection persisted for 80 days and the second for 62 day...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection, genetics and evolution genetics and evolution, 2021-03, Vol.88, p.104684-104684, Article 104684
Hauptverfasser: Abu-Raddad, Laith J., Chemaitelly, Hiam, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A., Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Yassine, Hadi M., Al Kuwari, Mohamed G., Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Bertollini, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or no symptoms. The first infection persisted for 80 days and the second for 62 days. Clearance of infection occurred 40 and 41 days, respectively, after development of detectable antibodies. Both cases were identified incidentally in an investigation of reinfection in a cohort of 133,266 laboratory-confirmed infected persons. •Two cases had substantial viral RNA concentration and conserved viral genome for ~2 months.•Infection clearance occurred >60 days after first positive swab.•Infection clearance occurred ~40 days after development of detectable antibodies.•Prolonged active infection was not associated with severity.
ISSN:1567-1348
1567-7257
DOI:10.1016/j.meegid.2020.104684